Chordate Medical ("Chordate", the "Company") has entered into an agreement with the market relations company Pharmore PSR LTD, Israel, to introduce the companys product for preventive migraine treatment on the Israeli market.
The agreement details that Pharmore will present the K.O.S treatment to opinion leaders within the neurology/migraine field and then develop a broader market position. The agreement also includes that Pharmore will manage the implementation of the companys previously communicated clinical follow-up study PM010 at two Israeli clinics. The agreement with Chordates former distributor has been terminated.
"Because we assess the conditions for achieving results faster, we have now chosen to work with a focused market access project in Israel, the same way as in the UK. The key people with neurology market expertise at our former distributor have formed Pharmore and are a natural contracting party for the continued assignment. According to our assessment, Pharmore possesses the necessary competence in the specialist area of neurology, the structure of the healthcare market, reimbursement matters and marketing", says Anders Weilandt, CEO of Chordate.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
The following documents can be retrieved from beQuoted
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel, and Saudi Arabia. Chordate Medicals share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.
N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.